CAGAYAN VALLEY CHD TB REFERENCE

LABORATORY OFFICIAL RESULT

CARIG NORTE, MAHARLIKA HIGHWAY,
TUGUEGARAO CITY, CAGAYAN

COVID-19 RT-PCR TEST OFFICIAL LABORATORY RESULT

NAME:   SIUAGAN, JAYVEE CABADDU

BIRTHDAY:   07/06/1999 AGE:   23
CIVIL STATUS:   SINGLE GENDER:   MALE
EMAIL:   cvchd.philhealth@gmail.com NATIONALITY:   PHILIPPINES, FILIPINO
ADDRESS:   81
B NEAR GASOLINE STATION, CONTACT NO.:   09760481966
MAHARLIKA HIGHWAY, CAGGAY, TUGUEGARAO PASSPORT NO.:   ________________________
CITY (CAPITAL), CAGAYAN, REGION II (CAGAYAN
VALLEY)

TYPE OF SPECIMEN:   OPS & NPS REGION:   REGION II (CAGAYAN VALLEY)

LABORATORY SERIAL NO:   23COVIDXPERT-5119 WARD:   ________________________
DATE & TIME OF COLLECTION:   06/05/2023 10:00 AM DATE ADMITTED:   _______________
DATE & TIME OF RECEIVED:   06/05/202304:48 PM REFERRING HEALTH FACILITY:   CAGAYAN
VALLEY
DATE & TIME OF PERFORMED:   06/05/2023 04:56 PM CENTER FOR HEALTH DEVELOPMENT TB
DATE & TIME OF RELEASED:   06/05/2023 04:57 PM/ REFERENCE LABORATORY

LABORATORY TEST RESULT: SARS-CoV-2 viral RNA DETECTED

POSITIVE
Comments/Remarks:
Please correlate this laboratory result with all the available clinical and epidemiological information A repeat or supplementary
specimen should be collected and test if there is high index of suspicion for COVID-19 viral infection. Significance: This test utilizes
specimen (ie. nasoparyngeal/oropharyngeal swab) collected from patients for the qualitative detection of SARS-CoV-2 viral RNA
Significance:
This test utilizes specimen (i.e. nasopharyngeal/oropharyngeal swab) collected from patients for the qualitative detection of SARS-
CoV-2 viral RNA
Limitations:
Viral RNA detection is dependent on the viral load extracted from the specimen and patient's disease course. Pre-analytic variables
such as but not limited to the collection, quality and transport of the specimen may also affect results. The performance
characteristics of this test have been validated and is continously being monitored by the Department of Health and COVID-19
Laboratories as part of its quality assurance procedures.
23COVIDXPERT-5119
Performed By: Validated By:
           
   
           
CLARISSE KEITH L. CALUBAQUIB, RMT SHIRLYN PEREZ, RMT, MPH
           
Medical Technologist Medical Technologist

Noted By:
 
BRENDALYN A. GALLEBO, MD, DPSP
20323-15477 Pathologist